INTERLEUCHINA-2 PEGHILATA NEL TRATTAMENTO DELLE NEOPLASIE SUPERFICIALE DELLA VESCICA. STUDIO DI FASE IB

Translated title of the contribution: Polyethyleneglycol-modified interleukin-2 in the treatment of superficial neoplasia of the bladder: Study in phase IB

A. Tubaro, A. Stoppacciaro, F. Velotti, C. Vicentini, R. Miano, A. Santoni, L. Ruco, L. Miano

Research output: Contribution to journalArticlepeer-review

Abstract

Twelve patients suffering from Ta-T1, N0 M0, G1-2, transitional cell carcinoma of the bladder received intravesical instillations of polyethylene-glycol-modified interleukin-2 (PEG-IL2) with tumor in situ (1/week x 6). An interpatient dose escalation scheme from 6 to 24 x 106 IU was used in four groups of three patients each. Transurethral resection of the bladder tumor was carried out 7-15 days after the last PEG-IL2 dose. Five out of twelve patients showed partial regression of the bladder neoplasm; stable disease was observed in the remaining 7; no tumor progression occurred. Two patients showed local tumor relapse 3 months after transurethral resection; no evidence of disease was found in the remaining 10 patients after 3-12 months follow-up (median 6, mean 7.5).

Translated title of the contributionPolyethyleneglycol-modified interleukin-2 in the treatment of superficial neoplasia of the bladder: Study in phase IB
Original languageItalian
Pages (from-to)69-70
Number of pages2
JournalActa Urologica Italica
Volume7
Issue numberSUPPL. 2
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Polyethyleneglycol-modified interleukin-2 in the treatment of superficial neoplasia of the bladder: Study in phase IB'. Together they form a unique fingerprint.

Cite this